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Abstract
Background: Non-cystic fibrosis bronchiectasis is characterised by sputum production, exercise limitation and
recurrent infections. Although pulmonary rehabilitation is advocated for this patient group, its effects are unclear.
The aims of this study are to determine the short and long term effects of pulmonary rehabilitation on exercise
capacity, cough, quality of life and the incidence of acute pulmonary exacerbations.
Methods/Design: This randomised controlled trial aims to recruit 64 patients with bronchiectasis from three
tertiary institutions. Participants will be randomly allocated to the intervention group (supervised, twice weekly
exercise training with regular review of airway clearance therapy) or a control group (twice weekly telephone
support). Measurements will be taken at baseline, immediately following the intervention and at six and 12 months
following the intervention period by a blinded assessor. Exercise capacity will be measured using the incremental
shuttle walk test and the six-minute walk test. Quality of life and health status will be measured using the Chronic
Respiratory Questionnaire, Leicester Cough Questionnaire, Assessment of Quality of Life Questionnaire and the
Hospital Anxiety and Depression Scale. The rate of hospitalisation will be captured as well as the incidence of
acute pulmonary exacerbations using a daily symptom diary.
Discussion: Results from this study will help to determine the efficacy of supervised twice-weekly pulmonary
rehabilitation upon exercise capacity and quality of life in patients with bronchiectasis and will contribute to clinical
practice guidelines for physiotherapists in the management of this population.
Trial registration: This study protocol is registered with ClinicalTrials.gov (NCT00885521).
Background
Bronchiectasis not related to cystic fibrosis (non-CF
bronchiectasis) is characterised by permanent dilatation
of the airways arising from bronchial inflammation and
infection [1]. Predominant symptoms include cough
with sputum production, dyspnoea and fatigue [2-4].
This clinical profile contributes to progressive decondi-
tioning, which gives rise to reduced exercise tolerance
and diminished health-related quality of life (HRQoL)
[2,5,6]. Patients with bronchiectasis suffer from recur-
rent acute exacerbations, which may require hospitalisa-
tion [7,8]. This clinical course of bronchiectasis imposes
considerable economic cost to the healthcare system
[9,10]. More importantly, the incidence of pulmonary
exacerbations is a prognostic predictor in bronchiectasis,
with progressive airway damage and decline in respira-
tory function greater in those experiencing a higher inci-
dence of acute exacerbations [11].
Medical intervention has limited impact on disease
progression or exercise capacity and evidence regarding
the cost effectiveness of any therapeutic approach in
bronchiectasis is scant [1]. Exercise and self manage-
ment training, as a component of a pulmonary rehabili-
tation (PR) program is a well-established and effective
intervention for patients with chronic obstructive pul-
monary disease (COPD), leading to reductions in the
incidence of acute exacerbations and reduced health
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care utilisation as well as improvements in exercise tol-
erance and HRQoL [12-16]. Although international
guidelines for PR recommend the inclusion of patients
with bronchiectasis within existing programs [12], there
is a lack of evidence supporting this practice [17]. One
study has compared exercise training with or without
inspiratory muscle training to standard medical care
[18]. While significant short-term improvement in exer-
cise capacity was demonstrated, benefits in HRQoL
were only achieved with a combination of whole body
exercise and inspiratory muscle training. The clinical
significance of these findings is unclear, as the adminis-
tered intervention differed from current recommenda-
tions for PR [12,19]. Although inspiratory muscle
training was applied as a form of airway clearance ther-
apy (ACT) in this study [18], no beneficial effects on
ease of sputum expectoration were demonstrated. The
long term benefits of PR which incorporates exercise
training and self management in ACT compared to
standard medical care, on exercise capacity and dimen-
sions of HRQoL, including fatigue, anxiety and depres-
sion remains unknown. Furthermore, evaluation of the
efficacy of such an intervention on the incidence of
acute pulmonary exacerbations of bronchiectasis may
provide evidence to determine best practice guidelines
in this patient population.
The primary aims of this study are to (1) determine
the short and long term effects of an eight-week PR pro-
gram consisting of supervised exercise training and self
management education in ACT compared to standard
care on exercise capacity and HRQoL; and (2) establish
the effect of this intervention on the incidence of acute
exacerbations over a 12 month period in patients with
bronchiectasis. We hypothesise that patients who com-
plete PR will have a higher exercise capacity and
HRQoL compared to standard care and that these bene-
fits will be sustained for up to six months. PR will also




This multi-centre, randomised controlled trial (RCT)
will be conducted at Alfred Health and Austin Health,
Melbourne, the Lung Institute of Western Australia and
Sir Charles Gairdner Hospital, Perth, Australia.
Participants
Inclusion/exclusion criteria
To be eligible for enrolment, participants must be aged
≥ 18 years and have a diagnosis of bronchiectasis that is
not attributable to CF, confirmed radiologically on high
resolution computed tomography. They must be clini-
cally stable, with no evidence of an exacerbation of
bronchiectasis or changes in medical therapy in the pre-
vious four weeks [7]. Other inclusion criteria comprise
of exertional dyspnoea (Modified Medical Research
Council (MMRC) score ≥ 1) [20] and a history of at
least two exacerbations per year over the past two years.
Participants will be excluded if they have 1) smoking
history ≥ 10 pack years or physician diagnosis of COPD
[21]; 2) a clinical diagnosis of asthma [22]; 3) interstitial
lung disease (clinical/radiological diagnosis); 4) medical
conditions which could place the individual at risk dur-
ing exercise testing or training (eg. unstable cardiovascu-
lar disease) or conditions that may restrict the
participant’s ability to exercise (eg. severe orthopaedic
or neurologic impairments; 5) participation in a PR pro-
gram within the last 12 months.
Sample size
To detect a true difference in the primary outcome
measures of maximal exercise capacity and HRQoL, a
total of 36 subjects (18 per group) will be required. This
is based on the 80% probability of detecting statistically
and clinically significant differences in maximal exercise
capacity (incremental shuttle walk test [ISWT]) [18] and
HRQoL (Chronic Respiratory Questionnaire [CRQ] total
score), according to pilot data from 33 patients with
bronchiectasis who completed PR at Alfred Health. To
detect a true difference for the secondary outcome mea-
sure of the incidence of acute exacerbations, a total of
64 subjects will be required. This is based on the 80%
probability of detecting a true difference in the number
of exacerbations between groups is 1.0 exacerbation,
with a SD of 1.4 exacerbations [11].
Recruitment and randomisation
The flow of participants through the study will reflect
the recommendations from the Consolidated Standards
of Reporting Trials statement [23] and is outlined in
Figure 1. Participants will receive written and verbal
information explaining the study and written consent
will be obtained from all participants. The Human
Research Ethics Committee of Alfred Health, Austin
Health and Sir Charles Gairdner Hospital approved the
study and the protocol is registered with ClinicalTrials.
gov (NCT00885521).
Participants will be screened from the Lung Institute
of Western Australia (LIWA) database of individuals
with bronchiectasis or during outpatient clinic visits to
Physiotherapy or Respiratory Medicine at Alfred Health,
Austin Health and Sir Charles Gairdner Hospital, by the
study investigators. If eligible, the study investigators
will approach the participant to explain the study and
gain written, informed consent. It will be explained that
they may withdraw from the study at any time. Within
strata, participants will be randomly assigned to receive
either standard care alone or PR. The strata are sputum
quantity (small volume: up to one tablespoon per day,
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large volume: > one tablespoon per day) and the site of
randomisation. The randomisation will be completed by
the creation of a random numbers table and individual
group assignment will be kept in sealed opaque envel-
opes. Following baseline assessments, a physiotherapist
will collect the appropriate envelope after confirming
sputum quantity. A computer-generated randomised
order for performing the field walking tests for each
participant will be determined before baseline measures
and adhered to throughout the study.
Intervention
Standard care group
These participants will receive instruction and review of
ACT provided by a senior physiotherapist. This process
is consistent with current clinical management at each
recruitment site. Each participant will be provided with
written information about bronchiectasis [24] and educa-
tion regarding self-management of the condition. Partici-
pants who have not been previously instructed in any
ACT will be taught the active cycle of breathing techni-
que [25]. Participants previously instructed in other
forms of ACT (eg. positive expiratory pressure therapy,
oscillating positive expiratory pressure therapy) will have
their technique reviewed, corrected if necessary and
encouraged to continue with this corrected technique for
the study duration. Instructions in ACT will be given
during the baseline assessment. These participants will
not receive any supervised exercise training but will be
informed at the baseline assessment that accumulating
30 minutes of moderate intensity physical activity on
most days of the week is the standard recommendation
Figure 1 Flow of patients through the study.
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for health benefits. During the eight-week intervention
period, participants will be contacted by telephone twice
weekly. The purpose of these calls is to answer any ques-
tions the participant may have regarding performance of
their ACT and to provide support and general health
advice using a standardised script. This is an accepted
strategy to control for clinician contact in trials involving
disabled patients with chronic lung disease and has been
previously used in patients with interstitial lung disease
[26]. No specific discussion related to physical activity
will be undertaken during these telephone calls.
Pulmonary rehabilitation group
Participants randomised to the PR group will receive
exercise training and regular instruction in self-man-
agement of ACT. No additional formal education ses-
sions will be included. Participants will receive the
identical instruction in ACT as described for the stan-
dard care group. Self management strategies to encou-
rage regular adherence with ACT will also be
implemented. Once a week at the conclusion of a PR
session, participants will record their daily sputum
volume on a 100 mm visual analogue scale and have
their ACT reviewed by a senior physiotherapist. This
will include observation of the participant’s technique
with correction where necessary and discussion of any
concerns or problems the participant is experiencing
with the self-management program.
The eight-week exercise training program will com-
prise of two supervised exercise classes at the institutions
each week with a home walking program on two addi-
tional days per week. The exercise program will follow
recent guidelines for exercise prescription in chronic
lung disease [19]. This will comprise of 30 minutes of
endurance exercise at each supervised session, including
walking and cycling. Initial walking intensity will be pre-
scribed at 75% of the maximal work rate achieved on the
ISWT while cycling intensity will be based on data
obtained from the 6-minute walk test (6MWT) [27]. For
participants unable to tolerate continuous exercise, inter-
val training will be used. Participants will also complete a
circuit of upper limb endurance exercises and functional
strength training for the lower limbs. An experienced
physiotherapist will monitor participants during the exer-
cise classes and progress the exercise within symptom
tolerance of dyspnoea and fatigue based on the 0 to 10
Borg scale [28]. Supplemental oxygen will be provided
during training if necessary to achieve an oxygen satura-
tion >85% [19]. Following the establishment of a safe,
supervised exercise regimen, a home exercise program
will be prescribed, with participants encouraged to walk
for 30 minutes at an intensity similar to that achieved in
the supervised sessions. Participants will record these
walking sessions in a home exercise diary. Attendance at
12 out of 16 supervised sessions will be considered
completion of the exercise intervention. At the comple-
tion of the intervention period, participants will be
instructed to continue with their home exercise program
three to five times per week and to record these sessions
in their exercise diary.
Outcome measures
All outcome measures will be recorded at baseline,
immediately following the intervention period (nine
weeks) and at six and 12 months post completion of the
intervention (Figure 1). Baseline data collection will
include age, gender, body mass index, usual ACT if pre-
viously prescribed and MMRC scale for dyspnoea [20].
The number of acute pulmonary exacerbations per year
in the previous two years will also be collated. An
exacerbation will be defined as an increase in clinical
signs and symptoms requiring alteration of medication,
including antibiotic therapy according to participant
recall and medical record review.
Primary outcome measures
The primary outcome measures are maximal exercise
capacity and HRQoL. An independent assessor, blinded
to group allocation will perform all outcome assess-
ments following the intervention period (nine weeks, six
and 12 months) which will be conducted over a two day
period at each time point.
a) Maximum exercise capacity will be measured with
the ISWT [29]. To allow for a learning effect, this test
will be performed twice, with a 30 minute rest period in
between each test. The primary outcome is the greatest
distance walked. The ISWT has demonstrated a moder-
ate to strong correlation with peak rate of oxygen
uptake [30], has shown responsiveness to change follow-
ing PR [12] and has been used in patients with non-CF
bronchiectasis [18].
b) HRQoL will be measured using the CRQ (self-
administered version) [31-33]. This disease-specific
questionnaire has demonstrated responsiveness to
change following PR [33]. The CRQ consists of 20 ques-
tions and assesses the domains of dyspnoea during
activities of daily living, fatigue, emotional function and
mastery, using a 7-point Likert scale and provides a
total HRQoL score. A higher score indicates better
HRQoL.
Secondary outcome measures
a) Cough specific HRQoL will be measured using the
Leicester Cough Questionnaire (LCQ). The LCQ mea-
sures the physical, psychological and social impact of
chronic cough [34]. It consists of 19 items with
responses based on a 7-point Likert scale and has been
validated in patients with non-CF bronchiectasis [35].
A higher score indicates less impact on HRQoL.
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b) Functional exercise capacity will be measured
using the 6MWT [36]. The distance walked (6 minute
walk distance, [6MWD]) has demonstrated strong corre-
lation with peak rate of oxygen uptake and maximum
work rate in patients with chronic respiratory disease
[27,30]. To allow for familiarisation (or learning effect),
two tests will be conducted using a standardised proto-
col [36] with the greatest distance recorded. The
6MWT is responsive to PR [12].
3) Anxiety and depression will be measured with the
Hospital Anxiety and Depression Scale (HADS). This
questionnaire is designed to detect and measure the
severity of anxiety and depression [37]. It consists of a
series of 14 statements, with responses based on a 4-
point Likert scale. The HADS is self-administered and
has demonstrated responsiveness to PR [38]. A higher
score is indicative of greater anxiety or depression.
4) HRQoL utility will be measured using the Assess-
ment of Quality of Life (AQOL) Questionnaire [39].
This measure reflects a patient’s HRQoL across five
dimensions: illness, independent living, social relation-
ships, physical senses and psychological well being [39].
It is comprised of 15 questions, with the life-death uti-
lity scale score ranging from 1.00 (reflecting best possi-
ble HRQoL equivalent state) and 0.00 (worse than death
equivalent state), which is then used to calculate quality
adjusted life years [39]. The AQOL has been validated
in different populations, but has not been previously
used in individuals with bronchiectasis.
5) Symptom diary. All participants will complete a
daily diary for the duration of the study, with the diaries
collected at the conclusion of each assessment. Partici-
pants will record a score for quantity and colour of
secretions expectorated each day. In addition, partici-
pants will also record if they have at least four of the
following clinical signs and symptoms suggestive of an
acute exacerbation of bronchiectasis [7] over two conse-
cutive days:
• Increase in sputum quantity
• Change in sputum colour
• Change in sputum viscosity
• Increase in cough
• Increase in dyspnoea
• Increase in fatigue/lethargy
• Fever (self-reported)
• Episode of haemoptysis
Participants will also record occasions of unplanned
review by their general practitioner or hospital admis-
sions (duration of hospitalisation) together with the pre-
scription of antibiotic therapy (days required) secondary
to a pulmonary exacerbation of bronchiectasis in their
symptom diary. These events will be cross-checked with
hospital and general practitioner medical records at the
conclusion of the study. Adjudication of a respiratory
exacerbation will be completed by an independent
investigator.
Spirometry will be performed in accordance with the
American Thoracic Society guidelines [40]. The highest
value for forced expiratory volume in one second (FEV1)
and forced vital capacity (FVC) obtained from three
reproducible trials will be recorded and compared to
predicted normal values. This will provide a measure of
the severity of airflow limitation and will be used to
assess stability of lung function over the duration of the
follow-up period of the study.
Statistical analysis
Data will be entered into SPSS (version 17.0; SPSS Inc;
Chi) for analysis. Descriptive statistics will be used to
examine the distribution and data that are not normally
distributed will be transformed or analysed using non-
parametric tests. Analyses will be conducted using an
intention to treat principle. Repeated measures analysis
of variance with planned comparison will be used to
compare all continuous variables that are normally dis-
tributed. Significant results will be analysed using post
hoc tests. Categorical variables will be analysed using the
chi square statistic. Relationships between outcome vari-
ables will be analysed using correlation coefficients. The
alpha level for all statistical analyses will be set at 0.05.
Discussion
Bronchiectasis has a heterogeneous clinical profile, sec-
ondary to the multiple aetiologies from which it may
originate [1,7]. Although the precise global prevalence is
unknown, bronchiectasis remains a cause of excessive
morbidity [8]. In the current climate of limited health
resources, it is important to provide interventions which
not only contribute to improved HRQoL, but positively
impact on disease progression and prognosis.
This research will be the first intervention study evalu-
ating the short and long term efficacy of PR, including
exercise training and self-management in ACT com-
pared to standard care, in patients with non-CF bronch-
iectasis. Currently, progression of respiratory symptoms
is evident in this heterogenous population despite opti-
mal medical intervention [8]. We recently found that
symptoms of chronic cough, sputum production and
fatigue, based on the St George’s Respiratory Question-
naire were associated with reduced exercise capacity in
patients with mild to moderate bronchiectasis [41]. This
implies that strategies such as a PR program which
incorporates self management and adherence to ACT
may have an equally positive impact on both diminished
exercise capacity and clinically relevant dimensions of
HRQoL, both of which will be important outcomes for
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all patients with bronchiectasis. Given the relationship
between exacerbation rate and decline in pulmonary
function [11], it would be highly significant if PR were
to impact on the incidence of acute exacerbations in
bronchiectasis. As both declining respiratory function
and reduced physical activity are associated with
increased mortality in this population [42], achieving a
reduction in the incidence of pulmonary exacerbations
would result in PR being one of the few available treat-
ments with the potential to modify the disease course
and prognosis in bronchiectasis and may be an inexpen-
sive complement to existing medical care.
The results of this study will assist in the development
of physiotherapy guidelines for the treatment of patients
with bronchiectasis in clinical practice. While a recent
survey revealed that the majority of physiotherapists in
Australia and New Zealand routinely prescribed a form
of ACT for patients with bronchiectasis, recommenda-
tions for exercise training were inconsistent [43]. In
addition, no specific guidelines exist to guide clinicians
in exercise prescription and the role of self management
in ACT for patients with bronchiectasis. If the study
findings are positive, the application of PR should be
routinely instituted for all patients.
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